1. Home
  2. AGIO vs SFNC Comparison

AGIO vs SFNC Comparison

Compare AGIO & SFNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • SFNC
  • Stock Information
  • Founded
  • AGIO 2007
  • SFNC 1903
  • Country
  • AGIO United States
  • SFNC United States
  • Employees
  • AGIO N/A
  • SFNC N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • SFNC Major Banks
  • Sector
  • AGIO Health Care
  • SFNC Finance
  • Exchange
  • AGIO Nasdaq
  • SFNC Nasdaq
  • Market Cap
  • AGIO 2.4B
  • SFNC 2.6B
  • IPO Year
  • AGIO 2013
  • SFNC N/A
  • Fundamental
  • Price
  • AGIO $41.33
  • SFNC $21.51
  • Analyst Decision
  • AGIO Hold
  • SFNC Hold
  • Analyst Count
  • AGIO 5
  • SFNC 4
  • Target Price
  • AGIO $52.50
  • SFNC $21.75
  • AVG Volume (30 Days)
  • AGIO 585.1K
  • SFNC 630.1K
  • Earning Date
  • AGIO 10-31-2024
  • SFNC 10-18-2024
  • Dividend Yield
  • AGIO N/A
  • SFNC 3.90%
  • EPS Growth
  • AGIO N/A
  • SFNC N/A
  • EPS
  • AGIO N/A
  • SFNC 1.19
  • Revenue
  • AGIO $31,306,000.00
  • SFNC $727,050,000.00
  • Revenue This Year
  • AGIO $44.80
  • SFNC N/A
  • Revenue Next Year
  • AGIO $174.95
  • SFNC $6.69
  • P/E Ratio
  • AGIO N/A
  • SFNC $17.79
  • Revenue Growth
  • AGIO 55.39
  • SFNC N/A
  • 52 Week Low
  • AGIO $19.80
  • SFNC $13.36
  • 52 Week High
  • AGIO $53.29
  • SFNC $22.45
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 37.77
  • SFNC 56.69
  • Support Level
  • AGIO $40.37
  • SFNC $20.78
  • Resistance Level
  • AGIO $46.24
  • SFNC $21.56
  • Average True Range (ATR)
  • AGIO 2.35
  • SFNC 0.56
  • MACD
  • AGIO -0.66
  • SFNC -0.05
  • Stochastic Oscillator
  • AGIO 7.39
  • SFNC 43.71

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

About SFNC Simmons First National Corporation

Simmons First National Corp is a financial holding company. The company through its subsidiaries is engaged in providing banking services including consumer, real estate and commercial loans, checking, savings and time deposits. The company's loan portfolio comprises construction, single-family residential and commercial loans; non-real estate loans, nonaccrual and past due loans; and credit card loans, student loans and other consumer loans. It also offers a range of products and services such as trust services, investments, agricultural finance lending, equipment lending, insurance, consumer finance and small business administration lending. All the business activity of the firm is functioned through the region of the United States.

Share on Social Networks: